Pro-Dex, Inc. Announces Fiscal 2024 Fourth Quarter and Full-Year Results

Rhea-AI Summary

Pro-Dex (NASDAQ:PDEX) reported strong financial results for Q4 and FY 2024. Q4 net sales increased 41% to $15.0 million, driven by a $3.4 million revenue boost from their largest customer. Q4 operating income rose 46% to $2.4 million. FY 2024 net sales grew 17% to $53.8 million, with operating income up 25% to $7.2 million. However, net income for FY 2024 decreased to $2.1 million ($0.60 per diluted share) from $7.1 million in FY 2023, primarily due to unrealized losses on marketable equity investments. The company highlighted successful growth despite transitioning to a multiple-facility operation and announced the hiring of a new Director of Operations to support future expansion.

Positive

• Q4 net sales increased 41% year-over-year to $15.0 million
• Q4 operating income rose 46% to $2.4 million
• FY 2024 net sales grew 17% to $53.8 million
• FY 2024 operating income increased 25% to $7.2 million
• Gross profit for FY 2024 increased 14% to $14.5 million

Negative

• Q4 gross margin decreased from 32% to 27% due to price pressures and increased indirect labor costs
• FY 2024 net income decreased 70% to $2.1 million, primarily due to unrealized losses on marketable equity investments
• Operating expenses for FY 2024 increased 6% to $7.4 million

Insights

Financial Analyst

Pro-Dex's Q4 and full-year results for FY2024 show significant growth in both revenue and operating income. Q4 net sales increased by 41% to $15.0 million, driven by a $3.4 million boost from their largest customer. The full-year revenue grew by 17% to $53.8 million.

Operating income for Q4 rose by 46% to $2.4 million and for the full year, it increased by 25% to $7.2 million. However, net income for the year dropped significantly due to $4.1 million in unrealized losses on marketable equity investments, compared to $3.9 million in gains the previous year.

The company's gross margin declined from 32% to 27% in Q4 due to price pressures and increased labor costs, which is a concern for profitability. The transition to a multi-facility operation and increased R&D expenses also impacted the bottom line, but these could be viewed as investments for future growth.

Medical Device Industry Expert

Pro-Dex's strong performance in the orthopedic market is evident from the substantial increase in both new unit sales and repair revenue from their largest customer. The $3.6 million increase in repair revenue highlights the success of their enhanced repair program for orthopedic handpieces, indicating a growing installed base and customer loyalty.

The company's focus on R&D, particularly in sustaining engineering activities, suggests ongoing product improvements and innovation. This is important in the competitive medical device industry. The hiring of a new Director of Operations with extensive manufacturing and supply chain experience is a strategic move to support their growth trajectory and potentially improve operational efficiency.

However, the pressure on gross margins due to pricing challenges and increased labor costs is a common industry trend that Pro-Dex will need to navigate carefully to maintain profitability while continuing to grow.

Investment Risk Analyst

While Pro-Dex's operational performance is strong, investors should be aware of several risk factors. The company's heavy reliance on its largest customer for growth exposes it to significant concentration risk. Any changes in this relationship could have a material impact on future performance.

The volatility in net income due to unrealized gains/losses on marketable equity investments is concerning. The $4.1 million unrealized loss this year, compared to a $3.9 million gain last year, demonstrates the potential for significant earnings volatility unrelated to core operations.

The declining gross margin, from 32% to 27%, indicates increasing cost pressures that could impact long-term profitability if not addressed. Additionally, the transition to a multi-facility operation may present integration challenges and potential inefficiencies in the short term.

Investors should closely monitor these factors alongside the company's growth initiatives to assess the risk-reward profile of Pro-Dex.

IRVINE, CA / ACCESSWIRE / September 5, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 fourth quarter and full-year ended June 30, 2024.

Quarter Ended June 30, 2024

Net sales for the three months ended June 30, 2024 increased $4.4 million, or 41%, to $15.0 million from $10.6 million for the three months ended June 30, 2023, due primarily to increased revenue in the amount of $3.4 million from our largest customer. Specifically, the increase relates to a $1.4 million increase in repair revenue related to the enhanced repair program we began last fiscal year to refurbish the orthopedic handpiece we sell to our largest customer, as well as an increase of $2.0 million in sales of new units to that same customer. Gross profit for the three months ended June 30, 2024 increased $729,000, or 22%. Although gross profit increased, our gross margin decreased from 32% for the three months ended June 30, 2023, to 27% for the three months ended June 30, 2024, due to continued price pressures and increased indirect labor in our operations group to manage our growth.

Operating expenses (which include selling, general and administrative, and research and development expenses) for the quarter ended June 30, 2024, remained relatively flat at $1.7 million, compared to $1.8 million for the prior fiscal year's corresponding quarter. While these total operating expense amounts have remained flat, we reduced general and administrative expenses by $182,000 and increased engineering expenses by $141,000 for the quarter ended June 30, 2024, compared to the corresponding quarter in 2023. The decrease in general and administrative expenses is a result of reduced equity compensation expenses due to employee forfeitures and the increase in engineering relates to a higher proportion of sustaining engineering expenses as opposed to billable customer contract expenses.

Our operating income for the quarter ended June 30, 2024, increased $742,000, or 46%, to $2.4 million compared to $1.6 million for the prior fiscal year's corresponding quarter. The increase reflects our increased sales and gross profit, as described above.

Net income for the quarter ended June 30, 2024, increased slightly by $86,000 to $1.6 million, or $0.46 per diluted share, compared to $1.5 million, or $0.42 per diluted share, in the corresponding quarter in 2023. The difference in the growth rate of net income and operating income is primarily due to unrealized gains and losses of investments. In the current quarter, operating income increased 46% over the corresponding quarter of the prior fiscal year compared to the slight increase in net income for the same period.

Year Ended June 30, 2024

Net sales for the fiscal year ended June 30, 2024 increased $7.8 million, or 17%, to $53.8 million from $46.0 million for the fiscal year ended June 30, 2023, due primarily to increases in revenue from our largest customer. Specifically, the increase relates to a $3.6 million increase in repair revenue as well as an increase of $3.5 million in sales of new units to that same customer.

Gross profit for the fiscal year ended June 30, 2024, increased $1.8 million, or 14%, to $14.5 million compared to $12.7 million for fiscal 2023.

Operating expenses (which include selling, general and administrative, and research and development expenses) for the fiscal year ended June 30, 2024, increased 6% to $7.4 million from $7.0 million in the prior fiscal year. The increase relates primarily to an increase in research and development costs because in fiscal 2024 our expenditures related primarily to sustaining engineering activities rather than billable customer projects which are reclassified to cost of sales.

Our operating income for the year ended June 30, 2024, increased $1.4 million, or 25%, to $7.2 million compared to $5.8 million for the prior fiscal year's corresponding quarter. The increase reflects our increased sales and gross profit, as described above.

Net income for the fiscal year ended June 30, 2024, was $2.1 million, or $0.60 per diluted share, compared to $7.1 million, or $1.95 per diluted share, for fiscal 2023. Our net income for the year ended June 30, 2024, contains unrealized losses on our marketable equity investments of $4.1 million while our net income for the year ended June 30, 2023, contains unrealized gains on our marketable equity investments of $3.9 million. The difference in the growth rate of net income and operating income is primarily due to unrealized gains and losses of investments. In the current fiscal year operating income increased 25% over the prior fiscal year, compared to the 70% decrease in net income for the same period. All of our investments are recorded at estimated fair value, and the valuation can be highly volatile.

CEO Comments

"We are very pleased with our performance including increasing sales and an increase of $1.4 million in operating income," said the Company's President and Chief Executive Officer Richard L. ("Rick") Van Kirk. "While this fiscal year included the challenges of transitioning to a multiple-facility operation, we continued to grow the business. I remain grateful to the entire Pro-Dex team for their ongoing efforts and teamwork."

Mr. Van Kirk continued, "Additionally, we are excited to announce that we hired a new Director of Operations in the first quarter of fiscal 2025, Mr. Jawahar Garg, who has extensive manufacturing operations and supply chain experience to assist our team to continue on our growth trajectory."

About Pro-Dex, Inc.:

Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered, and electric multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. We have patented adoptive torque-limiting software and proprietary sealing solutions which appeal to our customers, primarily medical device distributors. Pro-Dex also sells rotary air motors. Pro-Dex's products are found in hospitals and medical engineering labs around the world. For more information, visit the Company's website at www.pro-dex.com.

Statements herein concerning the Company's plans, growth and strategies may include "forward-looking statements" within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance (including, but not limited to, prospects for future growth) as well as management's expectations, beliefs, plans, estimates, or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company's actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the disclosure concerning the operational and business risks of the Company set forth in the Company's filings with the Securities and Exchange Commission.

(tables follow)

PRO-DEX, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS
(In thousands, except share data)

		June 30,
		2024				2023
ASSETS
Current assets:
Cash and cash equivalents		$	2,631			$	2,936
Investments			4,217				1,134
Accounts receivable			13,887				9,952
Deferred costs			262				494
Inventory			15,269				16,167
Prepaid expenses			345				296
Total current assets			36,611				30,979
Land and building, net			6,155				6,249
Equipment and improvements, net			5,024				5,079
Right of use asset, net			1,473				1,872
Intangibles, net			54				81
Deferred income taxes, net			1,555				-
Investments			1,563				7,521
Other assets			42				42
Total assets		$	52,477			$	51,823
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable		$	4,513			$	2,261
Accrued liabilities			3,359				3,135
Income taxes payable			632				453
Deferred revenue			14				-
Notes payable			4,374				3,827
Total current liabilities			12,892				9,676
Non-current liabilities:
Lease liability, net of current portion			1,182				1,638
Deferred income taxes, net			-				8
Notes payable, net of current portion			7,536				8,911
Total non-current liabilities			8,718				10,557
Total liabilities			21,610				20,233
Commitments and Contingencies:
Shareholders' equity:
Common stock, no par value, 50,000,000 shares authorized; 3,363,412 and 3,545,309 shares issued and outstanding at June 30, 2024 and 2023, respectively			3,917				6,767
Retained earnings			26,950				24,823
Total shareholders' equity			30,867				31,590
Total liabilities and shareholders' equity		$	52,477			$	51,823

PRO-DEX, INC. AND SUBSIDIARY
CONSOLIDATED INCOME STATEMENTS
(In thousands, except per share data)

		Three Months Ended June 30, (Unaudited)								Years Ended June 30,
		2024				2023				2024				2023
Net sales		$	15,025			$	10,639			$	53,844			$	46,087
Cost of sales			10,936				7,279				39,293				33,338
Gross profit			4,089				3,360				14,551				12,749
Operating expenses:
Selling expenses			37				9				117				155
General and administrative expenses			864				1,046				4,072				4,028
Research and development costs			836				695				3,189				2,804
Total operating expenses			1,737				1,750				7,378				6,987
Operating income			2,352				1,610				7,173				5,762
Interest expense			(150	)			(145	)			(558	)			(533	)
Unrealized gain (loss) on investments			(340	)			492				(4,125	)			3,899
Gain on sale of investments			-				-				-				6
Interest and dividend income			68				58				144				294
Income before income taxes			1,930				2,015				2,634				9,428
Income tax expense			343				514				507				2,354
Net income		$	1,587			$	1,501			$	2,127			$	7,074
Basic & Diluted income per share:
Basic net income per share		$	0.47			$	0.42			$	0.61			$	1.98
Diluted net income per share		$	0.46			$	0.42			$	0.60			$	1.95
Weighted average shares outstanding:
Basic			3,400,767				3,545,309				3,498,807				3,571,044
Diluted			3,473,167				3,610,109				3,571,207				3,636,944

PRO-DEX, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)

		Years Ended June 30,
		2024				2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income		$	2,127			$	7,074
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization			1,160				857
Unrealized (gain) loss on marketable equity investments			4,125				(3,899	)
Gain on sale of investments			-				(6	)
Non-cash lease recovery			(17	)			(2	)
Amortization of loan fees, net			(13	)			12
Share-based compensation			605				766
Deferred income taxes			(1,563	)			264
Changes in operating assets and liabilities:
Accounts receivable			(3,935	)			5,432
Deferred costs			232				216
Inventory			898				(3,489	)
Prepaid expenses			(49	)			494
Accounts payable and accrued expenses			2,436				(1,153	)
Deferred revenue			14				(1,013	)
Income taxes payable			179				(91	)
Net cash provided by operating activities			6,199				5,462
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of equipment and improvements			(983	)			(974	)
Proceeds from sale of investments			-				89
Investment in Monogram			(1,250	)			-
Net cash used in investing activities			(2,233	)			(885	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments on notes payable			(4,816	)			(6,093	)
Borrowing from Minnesota Bank & Trust, net of loan origination fees			4,000				5,284
Repurchases of common stock			(3,505	)			(1,547	)
Payments of employee taxes on net issuance of common stock			-				(223	)
Proceeds from exercise of stock options and ESPP contributions			50				89
Net cash used in financing activities			(4,271	)			(2,490	)
Net increase (decrease) in cash and cash equivalents			(305	)			2,087
Cash and cash equivalents, beginning of year			2,936				849
Cash and cash equivalents, end of year		$	2,631			$	2,936

Contact: Richard L. Van Kirk, Chief Executive Officer
(949) 769-3200

SOURCE: Pro-Dex, Inc.

View the original press release on accesswire.com

FAQ

What was Pro-Dex's (PDEX) Q4 2024 revenue?

Pro-Dex's Q4 2024 revenue was $15.0 million, a 41% increase from $10.6 million in Q4 2023.

How did Pro-Dex's (PDEX) net income change in FY 2024?

Pro-Dex's net income for FY 2024 decreased to $2.1 million ($0.60 per diluted share) from $7.1 million ($1.95 per diluted share) in FY 2023, primarily due to unrealized losses on marketable equity investments.

What was Pro-Dex's (PDEX) operating income for FY 2024?

Pro-Dex's operating income for FY 2024 increased 25% to $7.2 million, compared to $5.8 million in FY 2023.

How much did Pro-Dex's (PDEX) gross profit increase in FY 2024?

Pro-Dex's gross profit for FY 2024 increased by $1.8 million, or 14%, to $14.5 million compared to $12.7 million for FY 2023.